Cerebrotendinous xanthomatosis in Spain: clinical, prognostic, and genetic survey
- 4 June 2011
- journal article
- case report
- Published by Wiley in European Journal of Neurology
- Vol. 18 (10) , 1203-1211
Abstract
Background and purpose: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disorder caused by mutations in the CYP27A1 gene resulting in sterol‐27‐hydroxylase deficiency. Current information about CTX is based mainly on case reports, with only few large series reported. Although perceived as a potentially treatable condition, efficacy of chenodeoxycholic acid plus statin therapy remains unclear. To perform a nationwide survey of confirmed cases, with a thorough analysis of genotype‐phenotype data and prognostic factors.Methods: Retrospective review of the clinical and epidemiological aspects and mutations of all the patients diagnosed since 1992 in the main reference centers for genetic testing of CTX in Spain.Results: Twenty‐five patients from 19 families were identified. An average delay of 19 years was observed between symptom onset and clinical diagnosis. Two main clinical subgroups were recognizable: a classic form (cerebellar and other supratentorial symptoms) and a spinal form (chronic myelopathy). Cholestanol levels did not correlate with clinical presentation, severity or response to therapy. Despite treatment, five patients died during follow‐up, one to 4 years after diagnosis. Thirteen different mutations were identified, with a higher frequency of p.R395C in Northwestern Spain and p.R405W in Southern Spain. None of the mutations could be associated with a particular clinical feature combination or prognosis.Conclusions: This is the first nationwide extensive series of CTX reported in Spain. The higher number of cases in some areas suggests a possible founder effect. Spinal forms had a less severe prognosis. A delayed diagnosis could contribute to the lack of significant response to treatment.Keywords
This publication has 23 references indexed in Scilit:
- Neurophysiological study in cerebrotendinous xanthomatosisMuscle & Nerve, 2011
- Four novel CYP27A1 mutations in seven Italian patients with CTXEuropean Journal of Neurology, 2010
- Chronic Diarrhea and Juvenile Cataracts: Think Cerebrotendinous Xanthomatosis and TreatPediatrics, 2009
- Normalisation of serum cholestanol concentration in a patient with cerebrotendinous xanthomatosis by combined treatment with chenodeoxycholic acid, simvastatin and LDH apheresisNeurological Sciences, 2004
- Early‐onset parkinsonism in cerebrotendinous xanthomatosisMovement Disorders, 2002
- Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosisBrain, 1999
- Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin.Journal of Clinical Investigation, 1993
- Chronic demyelinating peripheral neuropathy in cerebrotendinous xanthomatosisAnnals of Neurology, 1986
- Long-Term Treatment of Cerebrotendinous Xanthomatosis with Chenodeoxycholic AcidNew England Journal of Medicine, 1984
- Rating neurologic impairment in multiple sclerosisNeurology, 1983